- Supported exchanges /
- NASDAQ /
- MBX.NASDAQ
MBX Biosciences, Inc. Common Stock (MBX NASDAQ) stock market data APIs
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Biosciences, Inc. Common Stock Financial Data Overview
23.5 | |
21.02 | |
- | |
24 | |
21.02 | |
16-27.5 | |
676 M | |
31 854 K | |
0 | |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
MBX Biosciences, Inc. Common Stock Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -50 717 000
- Earnings Per Share -1.48
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get MBX Biosciences, Inc. Common Stock Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get MBX Biosciences, Inc. Common Stock End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: